Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria

Karl Anderson, Alvito P. Alvares, Shigeru Sassa, Attallah Kappas

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The mean plasma half-life (T 1 2) of antipyrine was prolonged (21.69 ± 1.92 hr) in a group of 10 patients with hereditary hepatic porphyria, 8 of whom had acute intermittent porphyria (AIP) confirmed by decreased erythrocyte uroporphyrinogen-l-synthetase (URO-S) activities and 2 of whom had mixed hepatic porphyria, in comparison to the mean of 20 normal control subjects (12.65 ± 0.86 hr, p < 0.01). Antipyrine T 1 2 was especially prolonged in patients with a history of more severe symptoms, but there was no correlation with the degree of elevation in urinary excretion of the porphyrin precursors δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). In 7 completely latent carriers of the AIP gene defect who had normal urinary ALA and PBG levels, the elimination rates of antipyrine from plasma were entirely normal. Phenylbutazone T 1 2s were normal 10 porphyric patients tested. These results demonstrate that the cytochrome P-450-dependent enzyme system for oxidizing antipyrine, but not that for phenylbutazone, is impaired in some AIP individuals in whom the gene defect for the disorder is clinically expressed and that this impairment may be related to the severity of the disease. The partial decrease in URO-S activity characteristic of AIP does not result in a profound or generalized decrease in hepatic cytochrome P-450 function, however, even when there is sufficient derangement in the hepatic heme biosynthetic pathway to lead to excessive excretion of chemical intermediates in the pathway.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume19
Issue number1
StatePublished - Jan 1976
Externally publishedYes

Fingerprint

Hepatic Porphyria
Acute Intermittent Porphyria
Antipyrine
Porphyrias
Uroporphyrinogens
Porphobilinogen
Phenylbutazone
Aminolevulinic Acid
Ligases
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Liver
Biosynthetic Pathways
Porphyrins
Heme
Genes
Half-Life
Erythrocytes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria. / Anderson, Karl; Alvares, Alvito P.; Sassa, Shigeru; Kappas, Attallah.

In: Clinical Pharmacology and Therapeutics, Vol. 19, No. 1, 01.1976, p. 47-54.

Research output: Contribution to journalArticle

Anderson, Karl ; Alvares, Alvito P. ; Sassa, Shigeru ; Kappas, Attallah. / Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria. In: Clinical Pharmacology and Therapeutics. 1976 ; Vol. 19, No. 1. pp. 47-54.
@article{f162eea89cea478ab1117fa9f01ae79c,
title = "Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria",
abstract = "The mean plasma half-life (T 1 2) of antipyrine was prolonged (21.69 ± 1.92 hr) in a group of 10 patients with hereditary hepatic porphyria, 8 of whom had acute intermittent porphyria (AIP) confirmed by decreased erythrocyte uroporphyrinogen-l-synthetase (URO-S) activities and 2 of whom had mixed hepatic porphyria, in comparison to the mean of 20 normal control subjects (12.65 ± 0.86 hr, p < 0.01). Antipyrine T 1 2 was especially prolonged in patients with a history of more severe symptoms, but there was no correlation with the degree of elevation in urinary excretion of the porphyrin precursors δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). In 7 completely latent carriers of the AIP gene defect who had normal urinary ALA and PBG levels, the elimination rates of antipyrine from plasma were entirely normal. Phenylbutazone T 1 2s were normal 10 porphyric patients tested. These results demonstrate that the cytochrome P-450-dependent enzyme system for oxidizing antipyrine, but not that for phenylbutazone, is impaired in some AIP individuals in whom the gene defect for the disorder is clinically expressed and that this impairment may be related to the severity of the disease. The partial decrease in URO-S activity characteristic of AIP does not result in a profound or generalized decrease in hepatic cytochrome P-450 function, however, even when there is sufficient derangement in the hepatic heme biosynthetic pathway to lead to excessive excretion of chemical intermediates in the pathway.",
author = "Karl Anderson and Alvares, {Alvito P.} and Shigeru Sassa and Attallah Kappas",
year = "1976",
month = "1",
language = "English (US)",
volume = "19",
pages = "47--54",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria

AU - Anderson, Karl

AU - Alvares, Alvito P.

AU - Sassa, Shigeru

AU - Kappas, Attallah

PY - 1976/1

Y1 - 1976/1

N2 - The mean plasma half-life (T 1 2) of antipyrine was prolonged (21.69 ± 1.92 hr) in a group of 10 patients with hereditary hepatic porphyria, 8 of whom had acute intermittent porphyria (AIP) confirmed by decreased erythrocyte uroporphyrinogen-l-synthetase (URO-S) activities and 2 of whom had mixed hepatic porphyria, in comparison to the mean of 20 normal control subjects (12.65 ± 0.86 hr, p < 0.01). Antipyrine T 1 2 was especially prolonged in patients with a history of more severe symptoms, but there was no correlation with the degree of elevation in urinary excretion of the porphyrin precursors δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). In 7 completely latent carriers of the AIP gene defect who had normal urinary ALA and PBG levels, the elimination rates of antipyrine from plasma were entirely normal. Phenylbutazone T 1 2s were normal 10 porphyric patients tested. These results demonstrate that the cytochrome P-450-dependent enzyme system for oxidizing antipyrine, but not that for phenylbutazone, is impaired in some AIP individuals in whom the gene defect for the disorder is clinically expressed and that this impairment may be related to the severity of the disease. The partial decrease in URO-S activity characteristic of AIP does not result in a profound or generalized decrease in hepatic cytochrome P-450 function, however, even when there is sufficient derangement in the hepatic heme biosynthetic pathway to lead to excessive excretion of chemical intermediates in the pathway.

AB - The mean plasma half-life (T 1 2) of antipyrine was prolonged (21.69 ± 1.92 hr) in a group of 10 patients with hereditary hepatic porphyria, 8 of whom had acute intermittent porphyria (AIP) confirmed by decreased erythrocyte uroporphyrinogen-l-synthetase (URO-S) activities and 2 of whom had mixed hepatic porphyria, in comparison to the mean of 20 normal control subjects (12.65 ± 0.86 hr, p < 0.01). Antipyrine T 1 2 was especially prolonged in patients with a history of more severe symptoms, but there was no correlation with the degree of elevation in urinary excretion of the porphyrin precursors δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). In 7 completely latent carriers of the AIP gene defect who had normal urinary ALA and PBG levels, the elimination rates of antipyrine from plasma were entirely normal. Phenylbutazone T 1 2s were normal 10 porphyric patients tested. These results demonstrate that the cytochrome P-450-dependent enzyme system for oxidizing antipyrine, but not that for phenylbutazone, is impaired in some AIP individuals in whom the gene defect for the disorder is clinically expressed and that this impairment may be related to the severity of the disease. The partial decrease in URO-S activity characteristic of AIP does not result in a profound or generalized decrease in hepatic cytochrome P-450 function, however, even when there is sufficient derangement in the hepatic heme biosynthetic pathway to lead to excessive excretion of chemical intermediates in the pathway.

UR - http://www.scopus.com/inward/record.url?scp=0017260773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017260773&partnerID=8YFLogxK

M3 - Article

C2 - 1245093

AN - SCOPUS:0017260773

VL - 19

SP - 47

EP - 54

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -